×
验证码:
换一张
忘记密码?
记住我
CORC
首页
科研机构
检索
知识图谱
申请加入
托管服务
登录
注册
在结果中检索
科研机构
合肥物质科学研究院 [23]
内容类型
期刊论文 [23]
发表日期
2022 [1]
2021 [4]
2019 [2]
2018 [1]
2017 [11]
2016 [3]
更多...
×
知识图谱
CORC
开始提交
已提交作品
待认领作品
已认领作品
未提交全文
收藏管理
QQ客服
官方微博
反馈留言
浏览/检索结果:
共23条,第1-10条
帮助
限定条件
专题:合肥物质科学研究院
第一署名单位
第一作者单位
通讯作者单位
已选(
0
)
清除
条数/页:
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
排序方式:
请选择
作者升序
作者降序
题名升序
题名降序
发表日期升序
发表日期降序
提交时间升序
提交时间降序
Ultrahigh Lithium Storage Capacity of Al2C Monolayer in a Restricted Multilayered Growth Mechanism
期刊论文
ACS APPLIED MATERIALS & INTERFACES, 2022, 卷号: 14
作者:
Lu, Ning
;
Wang, Kai
;
Jiang, Jiaxin
;
Guo, Hongyan
;
Zuo, Gui Zhong
收藏
  |  
浏览/下载:14/0
  |  
提交时间:2022/12/23
two-dimensional functional material
lithium storage
anode material
lithium batteries
first-principles computation
Efficacy and safety of niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer with complete or partial response to the last platinum-based chemotherapy: a subgroup analysis of the phase III NORA trial
期刊论文
GYNECOLOGIC ONCOLOGY, 2021, 卷号: 162
作者:
Yang, Jiaxin
;
Wu, Xiaohua
;
Zhu, Jianqing
;
Song, Liang
;
Feng, Yanling
收藏
  |  
浏览/下载:46/0
  |  
提交时间:2021/11/01
Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer and a time-to-progression after penultimate platinum-based chemotherapy of 6-12 or > 12 months: a subgroup analysis of the phase III NORA trial
期刊论文
GYNECOLOGIC ONCOLOGY, 2021, 卷号: 162
作者:
Huang, Qidan
;
Wu, Xiaohua
;
Zhu, Jianqing
;
Wang, Danqing
;
Yang, Jiaxin
收藏
  |  
浏览/下载:43/0
  |  
提交时间:2021/11/01
Safety assessment of niraparib individualized starting dose in patients with platinum-sensitive recurrent ovarian cancer: A randomized, double-blind, placebo-controlled, phase III NORA trial.
期刊论文
JOURNAL OF CLINICAL ONCOLOGY, 2021, 卷号: 39
作者:
Wang, Jing
;
Wu, Xiaohua
;
Zhu, Jianqing
;
Yin, Rutie
;
Yang, Jiaxin
收藏
  |  
浏览/下载:26/0
  |  
提交时间:2022/01/10
Efficacy of niraparib maintenance therapy in Chinese women with platinum-sensitive recurrent ovarian cancer with and without secondary cytoreductive surgery: Results from the NORA trial.
期刊论文
JOURNAL OF CLINICAL ONCOLOGY, 2021, 卷号: 39
作者:
Wu, Lingying
;
Wu, Xiaohua
;
Zhu, Jianqing
;
Yin, Rutie
;
Yang, Jiaxin
收藏
  |  
浏览/下载:27/0
  |  
提交时间:2022/01/10
Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML)
期刊论文
CANCER BIOLOGY & THERAPY, 2019, 卷号: 20, 期号: 6, 页码: 877-885
作者:
Wu, Jiaxin
;
Wang, Aoli
;
Li, Xixiang
;
Chen, Cheng
;
Qi, Ziping
收藏
  |  
浏览/下载:30/0
  |  
提交时间:2019/11/27
BCR-ABL
PDGFR
chronic myeloid leukemia
kinase inhibitor
Repurposing cabozantinib to GISTs: Overcoming multiple imatinib-resistant cKIT mutations including gatekeeper and activation loop mutants in GISTs preclinical models
期刊论文
CANCER LETTERS, 2019, 页码: 105-114
作者:
Lu, Tingting
;
Chen, Cheng
;
Wang, Aoli
;
Jiang, Zongru
;
Qi, Ziping
收藏
  |  
浏览/下载:16/0
  |  
提交时间:2020/07/14
cKIT T670I mutant
Activation loop mutants
Drug resistance
Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino) cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl) tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor
期刊论文
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 卷号: 158, 页码: 896-916
作者:
Wang, Beilei
;
Wu, Jiaxin
;
Wu, Yun
;
Chen, Cheng
;
Zou, Fengming
收藏
  |  
浏览/下载:69/0
  |  
提交时间:2019/12/25
CDK9
Kinase inhibitor
Structure-activity relationship
Leukemia
Discovery of 1-(4-(4-Amino-3-(4-(2-morpholinoethoxy)-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)-3-(5-(tert-butyl)isoxazol-3-yl)urea (CHMFL-FLT3-213) as a Highly Potent Type II FLT3 Kinase Inhibitor Capable of Overcoming a Variety of FLT3 Kinase Mutants in FLT3-ITD Positive AML
期刊论文
JOURNAL OF MEDICINAL CHEMISTRY, 2017, 卷号: 60, 期号: 20, 页码: 8407-8424
作者:
Wang, Aoli
;
Li, Xixiang
;
Chen, Cheng
;
Wu, Hong
;
Qi, Ziping
收藏
  |  
浏览/下载:46/0
  |  
提交时间:2019/06/17
Discovery of N-(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR associated drug resistant mutants in NSCLC
期刊论文
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, 卷号: 139, 期号: 无, 页码: 674-697
作者:
Chen, Yongfei
;
Wu, Jiaxin
;
Wang, Aoli
;
Qi, Ziping
;
Jiang, Taoshan
收藏
  |  
浏览/下载:775/0
  |  
提交时间:2018/08/17
Egfr
Alk
Dual Kinase Inhibitor
Non-small Cell Lung Cancer
©版权所有 ©2017 CSpace - Powered by
CSpace